John Theurer Cancer Center to present 37 studies at the 2012 ASH Annual Meeting

December 07, 2012

Hackensack, N.J. (December 6, 2012) - Remaining at the forefront of blood cancer research, John Theurer Cancer Center at HackensackUMC, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 37 blood cancer studies at the 2012 American Society of Hematology (ASH) Annual Meeting being held in Atlanta from December 8-11.

"The research we are presenting at this year's ASH annual meeting underscores our commitment to bring patients access to promising novel therapies," said Andre Goy, M.D., M.S., who is chairman and director and chief of lymphoma, John Theurer Cancer Center and a Physician member of Regional Cancer Care Associates. "It is an exciting time in oncology given the expanding panoply of new medicines that are currently in development, many of which are taken orally, with less side effects and offering new possibilities to improve our patients quality of life and outcome."

ASH is the world's largest professional society concerned with the causes and treatments of blood disorders. Nearly one-third of the presentations showcased at the ASH annual meeting by John Theurer Cancer Center have been considered exceptionally significant and will be presented orally, including Phase I and Phase II studies, and multi-center and international trials in collaboration with leading cancer institutions such as the National Cancer Institute, Dana-Farber Cancer Institute, Mayo Clinic and MD Anderson.

"John Theurer Cancer Center's early drug discovery program is part of many of the exciting developments at this year's ASH, including second generation proteasome inhibitors, such as oprozomib and lenalidomide, and other emerging agents, such as selective kinase inhibitor GS-1101, BTK inhibitor ibrutinib, and SYK inhibitor fostamatinib," said Dr. Goy.

The research presented by Regional Cancer Care Associates physicians at John Theurer Cancer Center will include advancements made in research and clinical trials in lymphoma, multiple myeloma, blood and marrow stem cell transplantation and leukemia. Regional Cancer Care Associates physicians at John Theurer Cancer Center are lead or senior author in 15 studies, including Andre Goy, M.D.; Michele Donato, M.D., collection facility medical director, blood and marrow transplantation; Tatyana Feldman, M.D., lymphoma oncologist; Stuart Goldberg, M.D., chief, leukemia; Robert Korngold, Ph.D., chief, research; Anthony Mato, M.D., director of our chronic lymphocytic leukemia program; Scott Rowley, M.D., chief, blood and marrow transplantation; David Siegel, M.D., Ph.D., chief, multiple myeloma.

"We are committed to contributing to blood cancer research through our own investigator-initiated research and collaborating with other institutions," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovation officer, professor and vice president of cancer services, John Theurer Cancer Center and President of Regional Cancer Care Associates. "I want to thank our physicians and research staff for their dedication, as well as all of the patients who participate in our studies."

For those attending the ASH annual meeting, visit John Theurer Cancer Center at Booth 3413. The following are abstracts and presentations at ASH annual meeting from John Theurer Cancer Center. For ongoing updates and complete list of abstracts, please visit

John Theurer Cancer Center 2012 ASH Abstracts:

Multiple Myeloma Stem Cell Transplantation Leukemia Hematologic Malignancies
About John Theurer Cancer Center at Hackensack University Medical Center

John Theurer Cancer Center at Hackensack University is among the nation's top 50 U.S. News and World Report Best Hospitals for cancer - the highest-ranked in New Jersey with this designation. It is New Jersey's largest and most comprehensive cancer center dedicated to the diagnosis, treatment, management, research, screenings, preventive care, as well as survivorship of patients with all types of cancer.

Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. The 14 specialized divisions feature a team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. The John Theurer Cancer Center provides comprehensive multidisciplinary care, state of the art technology, access to clinical trials, compassionate care and medical expertise--all under one roof. Physicians at the John Theurer Cancer Center are members of Regional Cancer Care Associates one of the nation's largest professional hematology/oncology groups. For more information please visit

Media Contact:

Amy Leahing

John Theurer Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to